The MICA-NKG2D axis in clear cell renal cell carcinoma bolsters MICA as target in immuno-oncology
Authors:
Open Access
- 3 August 2022
- journal article
- research article
- Published by Taylor & Francis in OncoImmunology
- Vol. 11 (1) , 2104991
Abstract
NKG2D is a major natural killer (NK) cell-activating receptor that recognizes eight ligands (NKG2DLs), including MICA, and whose engagement triggers NK cell effector functions. As NKG2DLs are upregulated on tumor cells but tumors can subvert the NKG2D-NKG2DL axis, NKG2DLs constitute attractive targets for antibody (Ab)-based immuno-oncology therapies. However, such approaches require a deep characterization of NKG2DLs and NKG2D cell surface expression on primary tumor and immune cells. Here, using a bioinformatic analysis, we observed that MICA is overexpressed in renal cell carcinoma (RCC), and we also detected an association between the NKG2D-MICA axis and a diminished overall survival of RCC patients. Also, by flow cytometry (FC), we observed that MICA was the only NKG2DL over-expressed on clear cell renal cell carcinoma (ccRCC) tumor cells, including cancer stem cells (CSC) that also coexpressed NKG2D. Moreover, tumor-infiltrating leukocytes (TIL), but not peripheral blood lymphoid cells (PBL) from ccRCC patients, over-expressed MICA, ULBP3 and ULBP4. In addition, NKG2D was downregulated on peripheral blood NK cells (PBNK) from ccRCC patients but upregulated on tumor-infiltrating NK cells (TINK). These TINK exhibited impaired degranulation that negatively correlated with NKG2D expression, diminished IFN-γ production, upregulation of TIM-3, and an impaired glucose intake upon stimulation with cytokines, indicating that they are dysfunctional, display features of exhaustion and an altered metabolic fitness. We conclude that ccRCC patients exhibit a distorted MICA-NKG2D axis, and MICA emerges as the forefront NKG2DL for the development of targeted therapies in ccRCC.Keywords
Funding Information
- GlaxoSmithKline
This publication has 92 references indexed in Scilit:
- Human renal cancer stem cellsCancer Letters, 2013
- Human NKG2D-ligands: cell biology strategies to ensure immune recognitionFrontiers in Immunology, 2012
- Adoptive Transfer of Autologous Natural Killer Cells Leads to High Levels of Circulating Natural Killer Cells but Does Not Mediate Tumor RegressionClinical Cancer Research, 2011
- Differential Mechanisms of Shedding of the Glycosylphosphatidylinositol (GPI)-anchored NKG2D LigandsJournal of Biological Chemistry, 2010
- Natural Killer Cell Cytotoxicity Is Suppressed by Exposure to the Human NKG2D Ligand MICA*008 That Is Shed by Tumor Cells in ExosomesCancer Research, 2010
- NKG2D Ligand Expression in Human Colorectal Cancer Reveals Associations with Prognosis and Evidence for ImmunoeditingClinical Cancer Research, 2009
- Tumour‐experienced T cells promote NK cell activity through trogocytosis of NKG2D and NKp46 ligandsEMBO Reports, 2009
- NKG2D-Deficient Mice Are Defective in Tumor Surveillance in Models of Spontaneous MalignancyImmunity, 2008
- MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myelomaProceedings of the National Academy of Sciences, 2008
- In Vivo Expression Pattern of MICA and MICB and Its Relevance to Auto-Immunity and CancerPLOS ONE, 2007